Filing Flows › Cytek Biosciences (CTKB) › Q3 2026 › vs Q3 2025
Cytek Biosciences (CTKB) Q3 2026 vs Q3 2025 (year over year)
Cytek Biosciences's revenue rose $936K (+2%) from $52.3M in Q3 2025 to $53.2M in Q3 2026. The biggest changes: Service +$1.9M (+13%); Product −$953K (-3%).
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $37.2M | $38.1M | −$953K | -3% |
| Service | $16.1M | $14.2M | $1.9M | +13% |
| Revenue | $53.2M | $52.3M | $936K | +2% |
| Other income, net | $1.5M | $1.4M | $92K | +6% |
| Income tax benefit | $811K | $2.3M | −$1.5M | -65% |
| Net loss | $6.1M | $5.5M | $619K | +11% |
| Costs & expenses | $61.7M | $61.5M | $167K | +0.3% |
| Operating costs | $61.7M | $61.5M | $167K | +0.3% |
| Cost of revenue | $22.0M | $24.7M | −$2.7M | -11% |
| Research & development | $9.4M | $9.0M | $399K | +4% |
| Sales & marketing | $11.9M | $11.7M | $245K | +2% |
| General & admin | $18.4M | $16.1M | $2.2M | +14% |
| Operating cash sources | $11.4M | $11.5M | −$36K | -0.3% |
| Depreciation & amortization | $2.1M | $1.9M | $195K | +10% |
| Share-based compensation | $4.9M | $5.6M | −$784K | -14% |
| Cash used in operations | $4.5M | $3.9M | $553K | +14% |
| Net loss absorbed | $6.1M | $5.5M | $619K | +11% |
| Working capital & other | $5.3M | $6.0M | −$655K | -11% |
Questions
How much did Cytek Biosciences's revenue grow year over year in Q3 2026?
Cytek Biosciences's revenue rose $936K (+2%) from $52.3M in Q3 2025 to $53.2M in Q3 2026.
What drove Cytek Biosciences's revenue change in Q3 2026?
Service +$1.9M (+13%); Product −$953K (-3%).